Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc. Earnings Recaps

DFTX 2 recaps
Next earnings: March 11, 2027 (estimated) · full calendar
Q3 2026 Nov 12, 2026

Definium shares fell 2.1% after the earnings call, a roughly flat reaction. The update included positive Phase 3 findings and regulatory progress, but the next major MDD readout remains ahead: ASCEND top-line data are expected in 2027.

Key takeaways
  • In VOYAGE, a single 100-microgram dose produced a 5.4-point placebo-adjusted improvement on the HAM-A at week 12 (p<0.0001); the 214-participant study met its primary and all key secondary endpoints.
  • In PANORAMA, the same dose produced a 5.1-point placebo-adjusted HAM-A improvement at week 12 (p<0.0001); the 245-participant study also met its primary and all key secondary endpoints.
  • Management said DT-120 was generally well tolerated in the completed double-blind phases of three studies, with no drug-related serious adverse events or suicidality signal; dosing sessions averaged about six hours.
  • The company is targeting an NDA filing in the first half of 2027. ASCEND, its second Phase 3 MDD study, is enrolling, with top-line data expected in 2027.
  • DT-120 has received two FDA breakthrough therapy designations, for GAD and MDD; the company also reported encouraging initial DT-402 signals in an open-label Phase 2a study in adults with autism spectrum disorder.
Q1 2026 May 8, 2026

MindMed’s shares fell 5.8% after the Q1 2026 earnings release, reflecting investor disappointment likely tied to cautious outlook and an implied deceleration in near-term progress given no new operational catalysts or guidance updates in the transcript.

Key takeaways
  • The company reiterated ongoing progress in its lead program DT120 ODT with multiple Phase III trials in MDD and GAD, including topline data expected later this quarter and in Q3.
  • Enrollment is complete or nearing completion in all key studies: EMERGE (149 participants), VOYAGE (214 participants), and PANORAMA exceeding 200 participants.
  • Clinical study designs remain powered to detect clinically meaningful placebo-adjusted differences; however, no updates on interim efficacy data or changes to timelines were provided.
  • Management emphasized the potential for durability of effect and upcoming data readouts but refrained from providing upward guidance or new visibility on commercialization or cash runway.
  • Lack of new positive operational developments or concrete catalysts likely contributed to investor caution, as reflected in the negative market reaction.